comparemela.com

Latest Breaking News On - Sensorion - Page 4 : comparemela.com

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Australian approval follows recent trial approval by regulatory authorities in France Regulatory News: Sensorion (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company which

Institut pasteurMary jane elliott jessica hodgsonCatherine leveauStrategic communicationsCochlear ltdDrug administrationInternational media relationsChief medical officerOrphan drug designationInvestigational new drugCisplatin induced ototoxicityCochlear limitedInvestor relations communicationJessica hodgson

Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the

United kingdomCity ofInstitut pasteurMary jane elliott jessica hodgsonCatherine leveauOtmane boussifGene therapy developmentInternational media relationsConsilium strategic communicationsRegulatory newsChief technical officerTherapy approach for hearing disordersCisplatin induced ototoxicityCochlear limitedInvestor relations communicationStrategic communications

Sensorion Publishes Results of Combined General Meeting Resolutions

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the

Institut pasteurMary jane elliott jessica hodgsonCatherine leveauInternational media relationsConsilium strategic communicationsRegulatory newsCombined general meetingGeneral meetingCisplatin induced ototoxicityCochlear limitedInvestor relations communicationStrategic communicationsJessica hodgson

Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 31, 2022

Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent

France generalInstitut pasteurMary jane elliott jessica hodgsonCatherine leveauStrategic communicationsInternational media relationsRegulatory newsCombined general meetingFrench commercial codeGeneral meetingAnnual general meetingCombined shareholder general meetingCochlear limitedInvestor relations communicationJessica hodgson

Sensorion Announces the Publication of Its 2021 Annual Financial Report

Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent

Institut pasteurMary jane elliott jessica hodgsonCatherine leveauInternational media relationsConsilium strategic communicationsRegulatory newsCochlear limitedInvestor relations communicationStrategic communicationsJessica hodgson

vimarsana © 2020. All Rights Reserved.